Generic Name and Formulations:
Rabies vaccine, inactivated 2.5IU/mL; pwd for IM inj after reconstitution; may contain trace amounts of bovine gelatin, chicken protein, neomycin, chlortetracycline, and amphotericin B.
Novartis Pharmaceuticals Corp
Indications for RABAVERT:
Preexposure immunization and post-exposure prophylaxis of rabies.
Adults and Children:
Adults: inject into deltoid area. Small children: inject into thigh. Preexposure immunization: 3 inj of 1mL IM each on day 0, 7, and either day 21 or 28. Booster: 1 dose as needed to maintain antibody titer (see literature). Post-exposure prophylaxis: a 5-dose regimen of 1mL IM given on days 0, 3, 7, 14, and 28 (give 1st dose with human rabies immunoglobulin at a separate site). If previously immunized: 2 inj of 1mL each on days 0 and 3 (no immune globulin needed).
Immunocompromised: may get suboptimal response (monitor titers). Postpone preexposure immunization during acute febrile illness or infection. Egg allergy. Have epinephrine inj (1:1000) available. Pregnancy (Cat.C).
Immunosuppressants: may get suboptimal response.
Local reactions, lymphadenopathy, headache, myalgia, malaise, dizziness, neuroparalytic events, anaphylaxis.
Single-dose vial—1 (w. diluent)
Endocrinology Advisor Articles
- Fasting Glycemic Variability Indicates Increased Risk for Type 2 Diabetes
- Heritability of BMI Stronger in Obesogenic Environments
- Domestic Refrigeration May Pose Underestimated Risk for Insulin Quality
- Sitagliptin Provides Better Glycemic Control Than Dapagliflozin in T2D With Renal Impairment
- Adverse Events Associated With Diazoxide Treatment for Congenital Hyperinsulinism
- Causes of Burnout in Resident Physicians Examined
- Thyroid Hormone Therapy Not Beneficial for Subclinical Hypothyroidism
- Bone-Derived Factors in the Treatment of Diabetes
- Bariatric Surgery Reduces Macrovascular Complications in Obesity, T2D
- Without Medicaid Expansion, Poor Patients Forgo Medical Care